恩替卡韦治疗慢性乙型肝炎肝纤维化疗效的研究

摘要
图/表
参考文献(16)
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：应用肝脏实时剪切波弹性成像和超声量化评分评价恩替卡韦治疗慢性乙型肝炎（CHB）肝纤维化的疗效。方法：87例符合抗病毒治疗指征的CHB患者，根据治疗前肝脏病理分期进行分组。在治疗前肝脏实时剪切波弹性成像和超声量化评分与肝脏病理分期进行组间比较，应用恩替卡韦抗病毒治疗96周后，肝脏实时剪切波弹性成像与超声量化评分进行组内比较。结果：87例CHB患者分3组：A组（S0，S1）12例，B组（S2，S3）64例，C组（S4）11例。抗病毒治疗前，超声量化评分和肝硬度随着肝纤维化病理分期的增加而增大，组间差异均具有统计学意义。肝脏超声量化评分和肝硬度与纤维化病理分期均存在较好的相关性。肝硬度和超声量化评分的曲线下面积（AUC）是0.89和0.78。恩替卡韦抗病毒治疗96周后，肝脏实时剪切波弹性成像和超声量化评分治疗后均比治疗前有显著性的下降，组间差异均具有统计学意义。治疗前与治疗后超声量化评分和肝硬度均为A组＜B组＜C组。结论：肝脏实时剪切波弹性成像和超声量化指标可以用来对恩替卡韦治疗CHB肝纤维化疗效进行评估。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	丁洋
	安子英
	王岁晶
	窦晓光

关键词 ： , 肝炎, 乙型, 慢性, 肝硬化, 超声检查, 多普勒, 彩色

Abstract：Objective: To evaluate the efficacy of entecavir anti-fibrosis treatment in chronic hepatitis B(CHB) with real-time shear wave elastography and ultrasound quantitative score. Methods: Eighty-seven CHB patients with antiviral treatment indications were enrolled. They were grouped by liver pathological staging before treatment. Real-time shear wave elastography and ultrasound quantitative score were compared with pathological staging between groups before treatment. Real-time shear wave elastography was compared with ultrasound quantitative score within groups after 96 weeks entecavir treatment. Results: Eighty-seven CHB patients were divided into three groups: group A(S0, S1) 12 patients, group B(S2, S3) 64 patients, and group C(S4) 11 patients. The parameters of stiffness and ultrasound quantitative score increased gradually with liver fibrosis exacerbation． The parameters of stiffness and ultrasound quantitative score of each pathological stage had statistically significant difference between groups. Both of these parameters were well correlated with the pathological change on the liver fibrosis． The areas under the curve for stiffness and ultrasound quantitative score were 0.89 and 0.78, respectively． The parameters of stiffness and ultrasound quantitative score obviously decreased after 96 weeks treatment vs before. The parameters of stiffness and ultrasound quantitative score of each pathological stage had statistically significant difference within groups. The parameters of stiffness and ultrasound quantitative score in three groups were group A＜group B＜group C. Conclusion: Real-time shear wave elastography and ultrasound quantitative score could be used to evaluate the efficacy of entecavir anti-fibrosis treatment in CHB.

Key words： Hepatitis B, chronic Liver cirrhosis Ultrasonography, Doppler, color

PACS:	Ｒ512.62
	Ｒ445.1

基金资助:国家“十二五”传染病重大专项（2012ZX10002003）。辽宁省自然科学基金（2014021007）。
辽宁省临床能力建设项目（LNCCC-A02-2014）。中国医科大学附属盛京医院自由研究者基金项目（201102）。
辽宁省传染性疾病转化医学研究中心建设（2014225020）。

通讯作者: 窦晓光，中国医科大学附属盛京医院感染科，110004。E-mail：guang40@163.com

作者简介: 丁洋（1976-），女，辽宁沈阳人，副主任医师。E-mail：dingy@sj-hospital.org

引用本文:

丁洋，安子英，王岁晶，窦晓光. 恩替卡韦治疗慢性乙型肝炎肝纤维化疗效的研究[J]. 中国临床医学影像杂志, 2016, 27(6): 407-410.
DINＧ　Ｙang, AN Zi-ying, WANG Sui-jing, DOU Xiao-guang. Efficacy evaluation of entecavir anti-fibrosis treatment in chronic hepatitis B with#br# real-time shear wave elastography and ultrasound quantitative score. JOURNAL OF CHINA MEDICAL IMAGING, 2016, 27(6): 407-410.

链接本文:

http://www.jccmi.com.cn/CN/ 或 http://www.jccmi.com.cn/CN/Y2016/V27/I6/407

[1]Brenner DA． Molecular pathologenesis of liver fibrosis[J]． Trans Am Clin Climatol Assoc, 2009, 120: 361-368．
[2]Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J]. Hepatology, 2010, 52(3): 886-93.
[3]Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis[J]. Best Pract Res Clin Gastroenterol, 2011, 25(2): 195-206.
[4]Terrault NA, Bzowej NH, Chang KM, et al. AASLD Guidelines for Treatment of Chronic Hepatitis B[J]. Hepatology, 2016, 63(1): 261-283.
[5]中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南[J]. 中华肝脏病杂志，2011，19（1）：13-24.
[6]李建志，李洁，熊春梅，等． Fibroscan测定与超声影像学检查在诊断慢性乙肝相关肝纤维化中的价值[J]．山东大学学报：医学版，2012，50（10）：115－118．
[7]张玲荣，郝彦琴，任姣龙，等. 慢性乙肝患者肝纤维化与肝硬度、超声量化指标、血清肝纤维化指标的相关性[J]．山西医科大学学报，2015，46（1）：45－48．
[8]王金锐，徐荣．肝纤维化诊断及疗效评估共识[J]．中华肝脏病杂志，2009，10（5）：327-328．
[9]Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity[J]. Vaccine, 2012, 30(12): 2212-2219.
[10]Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859): 2095-2128.
[11]Parsons CJ, Takashima M, Rippe RA． Molecular mechanisms of hepatic fibrogenesis[J]． J Gastroenterol Hepatol, 2007, 22(Suppl 1): S79-S84．
[12]Saleh HA, Abu-Ｒashed AH． Liver biopsy remains the gold standard for evaluation of chronic hepatitis and fibrosis[J]． J Gastrointestin Liver Dis, 2007, 16(4): 425－426．
[13]Jeong JY, Kim TY, Sohn JH, et al. Real time shear wave elastography in chronic liver diseases: Accuracy for predicting liver fibrosis, in comparison with serum markers[J]. World J Gastroenterol, 2014, 20(38): 13920-13929.
[14]Jung KS, Kim SU． Clinical applications of transient elastography[J]． Clin Mol Hepatol, 2012, 18(2): 163－173．
[15]Muller M, Gennisson JL, Deffieux T, et al. Quantitative viscoelasticity mapping of human liver using supersonic shear imaging: preliminary in vivo feasibility study[J]. Ultrasound Med Biol, 2009, 35(2): 219-229.
[16]Ling W, Lu Q, Quan J, et al. Assessment of impact factors on shear wave based liver stiffness measurement[J]. Eur J Radiol, 2013, 82(2): 335-341.